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Autosomal dominant polycystic kidney disease is largely due to mutations in PKD1. PKD1 has an unusual genomic structure, including a 2.5-kb
polypyrimidine sequence in intron 21, which has been postulated to lead to a high rate of spontaneous genomic mutation events. In addition, the
majority of the gene is duplicated three to six times at 97–99% identity elsewhere in the genome. To identify genomic mutations in PKD1, we
developed a multiplex ligation-dependent probe assay (MLPA) in which sites of variation between PKD1 and its copies were positioned at the
ligation sites of the MLPA probe sets. Thirteen probe sets covered PKD1 exons 2 through 46, at an average spacing of 2.5 kb. Analysis of 27
independent PKD patient samples showed no evidence for genomic deletions confined to PKD1.Analysis of 15 tuberous sclerosis patient samples in
which deletions in TSC2 extended into PKD1 showed no evidence of clustering of breakpoints near the polypyrimidine tract.
© 2007 Elsevier Inc. All rights reserved.Keywords: PKD1; TSC2; MLPA; Large deletions; Polypurine–polypyrimidine tract; Intron 21; Autosomal dominant polycystic kidney disease; Multiplex ligation-
dependent probe amplificationAutosomal dominant polycystic kidney disease (ADPKD) is
a common genetic disease and accounts for approximately 10%
of end-stage renal disease in the United States [1]. ADPKD is
caused by mutations in either the PKD1 gene, which account
for approximately 85% of ADPKD families (MIM 601313), or
the PKD2 gene, which account for about 15% of families (MIM
173910), based upon linkage analyses [2,3].
The PKD1 gene has an unusual genomic structure (Figs. 1A
and 2A). It consists of 46 exons, of which the last 45 are found in a
relatively compact 31 kb on 16p13.3, directly adjacent to the
TSC2 gene. PKD1 and TSC2 are in opposite transcriptional ori-
entations, such that their 3′ UT regions overlap by a few nu-
cleotides [4]. The first exon of PKD1 is located 16 kb away from
exon 2, with a relatively large intron 1.Moreover, the region from
intron 1 to exon 33 of PKD1 is segmentally duplicated six times
elsewhere on chromosome 16 at 97–99% identity [5,6]. In ad-⁎ Corresponding author. Current address: Laboratory of Cancer Genetics,
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doi:10.1016/j.ygeno.2007.10.003dition, PKD1 exon 1 and the adjacent intron 1 sequence are
segmentally duplicated three times at 99% identity.
These genomic features have greatly complicated mutation
analysis of PKD1 in ADPKD patients, necessitating complex
design strategies, including long-range PCR preamplification
using unique sequence elements and other approaches.With these
measures, comprehensive mutation analyses of PKD1 indicate
that about 50–60% of patients meeting the diagnostic criteria for
ADPKD will have a small (including indels of size b30 bp)
mutation found in PKD1 [7]. One recent small series was able to
identify 100% of mutations in Finnish PKD patients, and 16 of 17
families showed both linkage to and mutation in PKD1 [8].
Another highly unusual feature of the PKD1 gene is the pre-
sence of a 2.5-kb polypurine–polypyrimidine sequence in intron
21 and another shorter, similar sequence in intron 20. The intron
21 sequence consists of 65% cytosine and 32% thymidine (97%
pyrimidine) on the coding strand and is one of the largest
intragenic tracts of this kind in the human genome. This sequence
has been shown to form various types of non-B DNA including
triplex DNA structures [9], confer plasmid instability in bacterial
systems [10], and interfere with DNA replication [11].
Fig. 1. Genomic structure of PKD1 and strategy for probe design in duplicated regions. (A) Genomic structure of PKD1, according to the UCSC genome browser (Mar
2006), with first (e1) and last (e46) exons indicated. Black and yellow bars indicate PKD1 fragments duplicated elsewhere in the genome at 97–98% and 98–99%
identity, respectively. (B) Sequence alignment for PKD1 exon 25 and six duplicated copies of that exon located elsewhere on chromosome 16. Blue and red highlight
matching and discordant nucleotides. Top: 5′ and 3′ half-probes are shown. Note that one of the nucleotides at the ligation position (position −1 in the 5′ half-probe,
A) is present only in the PKD1 copy, not in the duplicates, by our design (additionally, the nucleotide at position −9 is PKD1 specific).
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would be associated with a higher than average rate of mutation
events, particularly genomic deletions. Rossetti et al. noted an
increase in point mutations in the vicinity of the tracts [7], and
there appears to be increased recombination and mutagenic
activity in the PKD1 region on 16p13.1 [12–14]. However,
limited surveys using Southern blot analysis have identified
genomic deletions of PKD1 in only a small fraction of ADPKD
patients [5,15].
Here we present the development of a comprehensive mul-
tiplex ligation-dependent probe assay (MLPA) to assess dele-
tions and duplications within the PKD1 gene. Due to the
extensive, nearly identical sequence repeats within PKD1, assay
design was challenging. We then studied cohorts of ADPKD
patients and a group of patients with the combined tuberous
sclerosis (TSC)–PKD syndrome [16,17]. Fifteen patients with
genomic deletions encompassing part of the PKD1 gene were
studied, and there was no evidence from the positions of the
deletion breakpoints that the intron 21 polypurine–polypyrimi-
dine tract played a role in the occurrence of these germ-line
deletions.
Results and discussion
To examine the frequency of genomic deletion mutations in
PKD1 and localize the breakpoints within the gene for such
deletions, we developed an MLPA to determine the copy
number of multiple exons within PKD1. Thirteen MLPA probes
were designed to cover exons 2 through 46 (3′ end) of thePKD1 gene, with an average interprobe spacing of 2.5 kb
(Fig. 2A). Several additional probes were also designed: 1 in
PKD1 intron 1, 2 in the 5′ upstream region of PKD1, and 2 in
exons 4 and 6 of PKD2.We also included as controls three probe
sets from other chromosomes [18]. The complete set of MLPA
probes consisted of 22 probes whose amplification products
ranged in size from 90 to 154 bp. The sequence of each probe
and its exact position are shown in Supplementary Table 1 and
Fig. 2A. To maximize the ability to discriminate between PKD1
exons and duplicated segments, nucleotides that varied between
these two sequences were placed in the probes at the ligation site
(see Materials and methods for further details) (Fig. 1B).
Extensive analysis on normal samples was performed to
demonstrate consistent signal intensity for these probes (Fig. 3A).
There was no evidence of large unexpected peaks reflecting
hybridization and subsequent amplification of probes at more
than one site per genome. In the course of this analysis, 12 probe
sets had to be modified or removed, due to variation in the size of
amplification peaks among different DNA samples. Such var-
iation in probe-set amplicon yield may have occurred for any of
several reasons: (1) unknown sequence variation in the PKD1
sequence chosen for primer design, (2) inaccuracies and/or se-
quence variation in the multiple copies of duplicated regions, or
(3) variable numbers of repeats of some of these sequences.
We then analyzed 60 DNA samples from ADPKD patients
from 27 families. In this set there were 4 samples that showed
evidence of copy number variation (Fig. 3B). Three of these
samples were from a single family, and all showed an apparent
deletion of exon 40 (Fig. 3B, sample 01-1090). DNA sequence
Fig. 2. Map of all PKD1 deletions. (A) Map of PKD1 and flanking regions. Exons are indicated by black vertical lines of width proportional to exon size. Thin blue
lines indicate the positions of PKD1 MLPA probes. The duplicated regions are indicated by the red line. (B) Deletion map. Each deletion mutation in PKD1 is
represented by a horizontal black/gray line indicating its extent, as mapped previously in TSC2 [18] and in PKD1 (this article). The black line indicates the minimum
deleted region, and the gray the possible extent to the next undeleted probe. For two mutations the breakpoints were identified by LRPCR/sequencing. (C) Cumulative
frequency of breakpoints within PKD1 as a function of linear distance. The positions of mutations were assigned to the midpoint of the distance between the last probe
showing deletion and the first probe not showing deletion. Note that breakpoints are distributed fairly evenly across PKD1 with none in intron 21 or 22, highlighted
with yellow background. Intron 21 contains the polypurine–polypyrimidine tract.
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presence of a previously unknown single-base deletion muta-
tion, c.11372delC, which was situated under the oligonucleotide
probe (9 bases from the ligation position), accounting for the
reduction in signal intensity by MLPA. The other sample
showed evidence of deletion for probes from PKD1 intron 1
through exon 46 (Fig. 3B, sample 18-1071). This patient had
features of TSC in addition to early onset ADPKD, consistent
with previous observations on the effects of genomic disruption
of both genes [17,18]. Thus, there were no intragenic genomic
deletions of PKD1 identified in this analysis.
We also examined 15 DNA samples from TSC patients who
had previously been studied using MLPA probe sets for TSC2
and shown to have deletions that extended into PKD1 [18]. The
extent of the deletions in PKD1 were entirely consistent with
our previous analysis, providing additional strong support for
the validity of this new PKD1 MLPA. These deletions were
found to extend a variable extent into the PKD1 gene (Figs. 2B,
C, and 3B). Four deletions extended through the entire PKD1gene, including both probe sets in the 5′ flanking region of
PKD1. The other 11 appeared to be randomly distributed across
the length of the gene. In particular, none of the breakpoints
were found in the region between the probes for exons 20 and
22, which contains the intron 21 polypurine–polypyrimidine
tract.
In conclusion, we developed a reliable and robust MLPA
analytic method for a region of the genome that is highly
repetitive. Although other strategies may be considered, we
found that designing the oligonucleotide probes to make the
ligated base overlie the site of sequence differences among
highly similar sequences was effective to permit discrimination
of unique sequence copy number. We observed greater variation
in the prenormalized peak heights (Fig. 3A) than seen in MLPA
probe sets designed for other genes [18], possibly reflecting
hybridization of probes to multiple sites in the genome or re-
hybridization of PKD1 exons to duplicated copies after de-
naturation. Nonetheless, the peak height patterns were highly
consistent, enabling detection of deletion mutations.
Fig. 3. Electropherograms and normalized peak height graphs for PKD1 MLPA. (A) Electropherograms of PKD1 MLPA. A control sample is shown at top. The sample
below has a deletion encompassing the entirePKD1 gene, with all peaks of reduced height indicatedwith an asterisk. The location of each probewithin the gene is shown: P1,
PKD1;T2,TSC2; P2,PKD2; e, exon; control, control probe; i, intron; 5′flank, 5′ flanking probe. The sizes of the amplified products are 90–154 nucleotides. (B) Normalized
peak height graphs for eight DNA samples. Each bar represents the normalized peak height for the probe indicated on the x axis, with control probes first, thenPKD1 probes,
then a TSC2 probe, then twoPDK2 probes. The heavy black lines indicate probes with reduced signal. Upper left is a control sample; next is an apparent single-exon deletion,
which proved to be a single-nucleotide deletion under the probe. The remainder are all deletions extending from TSC2 variable distances into the PKD1 gene.
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in PKD1 are relatively rare. We found none among 60 ADPKD
patients belonging to 27 families, 12 of whom were from a
population enriched for such mutations by prior PKD1 small
mutation screening. This matches well with previous analyses
of PKD patients that employed Southern blot analysis, with
findings of 3 of 124 (2.4%) deletions [15]. By comparison, we
recently completed a comprehensive survey for genomic de-
letion mutations in TSC patients and found that 6.5% of TSC
patients had genomic deletion/duplication mutations in TSC1 or
TSC2 [18]. In addition, in that study, 21 of 54 (39%) patients
with such mutations had a deletion that encompassed portions
of both TSC2 and PKD1. The inference is that most genomic
deletions occurring in PKD1 are relatively large, extending to
include the neighboring TSC2 gene and presenting early in life
with both TSC and early onset PKD [17].
It is notable that this PKD1 MLPA probe set now enables a
search for deletion mutations within PKD1 at a small fraction
of the cost, effort, and DNA quantity required for Southern
blot analysis. In addition, the method that we have described
for generation of MLPA probe sets that can distinguish be-
tween closely related genomic sequences, by placing variant
nucleotides at the ligation site of the MLPA probe sets, can be
adapted for use in the analysis of any repetitive genomic
sequence as long as there are some variant nucleotides among
the copies.
Although the total number of independent samples studied
was small, we found no evidence for an enhanced rate of
genomic deletion events near the polypurine–polypyrimidine
tract present in intron 21 of PKD1. A more global destabilizing
effect is possible, leading to deletions that extend across or are
nearby this tract. However, it is difficult to provide clear evidence
for this potential mechanism. In addition, we did not examine
somatic mutations in PKD1 in renal tubule cells. Such somatic
mutations are thought to be a critical step in the pathogenesis of
cyst development in PKD patients, since cyst-lining cells often
demonstrate loss of heterozygosity at the PKD1 locus [19,20].
The polypurine–polypyrimidine tract may contribute to somatic
mutagenesis of PKD1 and cyst development.Materials and methods
Patient samples
Several sets of DNA samples from human subjects were available for this
study, all collected after HRC-approved informed consent. Forty-eight ADPKD
patients from 15 families were collected by J.B. in Cincinnati, Ohio, USA, and all
met conventional diagnostic criteria for this condition. Twelve ADPKD patients
were collected by Y.P. in Toronto, Ontario, Canada. These 12 patients were part
of a larger set of 23 ADPKD patients who were screened for PKD1 and PKD2
mutations by direct sequencing (Athena Diagnostics, Inc.) and in 11 of whom
mutations were identified (unpublished data). Fifteen tuberous sclerosis patients
were collected by D.J.K. and collaborators and were previously shown to have
genomic deletions of TSC2 that extended into PKD1 [18].
PKD1 MLPA design
MLPA oligonucleotide probes were designed to assess copy number at
multiple sites within the PKD1 gene. Each probe was composed of two 5′ and 3′half-probes, each containing unique target-specific sequence, stuffer sequence,
and universal primer sequences on their 5′ and 3′ ends, respectively [21]. The
probe design strategy was as described previously [18] except that additional
analysis was performed for probes located in the duplicated regions of PKD1.
Candidate sequences for probes in duplicated regions were compared (BLASTN
algorithm with Expect=1 and without filtering) against the reference human
genome sequence. Highly homologous repeat copies were then all aligned at
once using MultiAlign (http://prodes.toulouse.inra.fr/multalin/multalin.html)
[22]. To maximize discrimination of PKD1 vs these other sequences by the
probe sets, probes were designed by placing variant nucleotides (between the
PKD1 sequence and the repeats) at the ligation position in 5′ or 3′ half-probes
(Fig. 1B). All probes were synthesized at 100 nM scale and purified by PAGE
(IDT, Skokie, IL, USA). To facilitate ligation, 3′ half-probes were synthesized
with a 5′ phosphate.
MLPA reactions
MLPA was performed as described previously [18], following the general
directions provided by MRC-Holland (www.mlpa.com), using a probe set to
cover the entire PKD1 gene. Briefly, 3.4 μl genomic DNA (20 ng/μl) was
incubated at 98 °C for 5 min. After the sample was cooled to room temperature,
1 μl of probe mix (containing 1 and 2 fmol of probes located in unique and
duplicated regions, respectively) and 1 μl of SALSA hybridization buffer were
added, and the solution was denatured at 95 °C for 2 min and hybridized at 60 °C
for 16 h. Hybridized probes were ligated at 54 °C for 15 min by addition of 21 μl
ligation mixture. Following heat inactivation, 7.5 μl of ligation reaction was
mixed with 22.5 μl of PCR buffer, heated to 60 °C, mixed with 7.5 μl PCR
mixture (SALSA polymerase, dNTPs, and universal primers, one of which was
labeled with fluorescein), and subjected to PCR amplification for 30 cycles. All
reagents except the synthesized oligonucleotide probes were obtained from
MRC-Holland.
Amplification products were diluted in water and then 1:9 in HiDi
formamide (ABI) containing 1/36 volume of ROX500 size standard (ABI) (final
dilution 20-fold) and then separated by size on an ABI 3100 genetic analyzer
(ABI). Electropherograms were analyzed by GeneMapper version 3.5 (ABI),
and peak height data were exported to an Excel table. Excel programs were
generated (available upon request) to transform the peak height data to nor-
malized values, such that control samples gave a value of 1 after normalization.
Briefly, peak heights for each probe were divided by the average signal from
three or more control probes (located on different chromosomes), and then that
value was divided by a similar value calculated from reference samples. We used
the average values from four reference samples without deletion in TSC2/PKD1
processed concurrently for each analysis.
DNA sequence analysis
DNA sequence analysis was performed using conventional Big Dye Se-
quencing by the BWH DNA Sequencing Core Facility.Acknowledgments
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